康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300601 康泰生物

已收盘 07-25 15:00:00

{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":17.55,"timestamp":1753426989000,"preClose":18.3,"halted":0,"volume":41076746,"delay":0,"changeRate":-0.041,"floatShares":900000000,"shares":1117000000,"eps":0.1523,"marketStatus":"已收盘","change":-0.75,"latestTime":"07-25 15:00:00","open":18,"high":18.12,"low":17.42,"amount":727000000,"amplitude":0.0383,"askPrice":17.55,"askSize":767,"bidPrice":17.54,"bidSize":567,"shortable":0,"etf":0,"ttmEps":0.1523,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":18.3,"symbolType":"stock","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":20.13,"lowLimit":16.47,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116928600,"isCdr":false,"pbRate":2.23,"roa":"--","peRate":115.233093,"roe":"0.23%","epsLYR":0.18,"committee":-0.096727,"marketValue":19602000000,"turnoverRate":0.0456,"status":1,"floatMarketCap":15802000000},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2550080611","title":"7月10日康泰生物涨7.01%，嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2550080611","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550080611?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:17","pubTimestamp":1752135471,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日康泰生物涨7.01%创60日新高，收盘报16.65元，换手率5.95%，成交量53.51万手，成交额8.87亿元。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为2.75亿元，最新净值0.6749，较上一交易日上涨0.01%，近一年上涨21.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000025136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300601","BK0239","BK0201","159646"],"gpt_icon":0},{"id":"2550611247","title":"康泰生物涨7.01%，中国银河一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2550611247","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550611247?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:17","pubTimestamp":1752135462,"startTime":"0","endTime":"0","summary":"今日康泰生物涨7.01%，收盘报16.65元。2025年7月3日，中国银河研究员程培,宋丽莹发布了对康泰生物的研报《PCV13获土耳其GMP认证，持续布局海外》，该研报对康泰生物给出“买入”评级。研报中预计公司2025-2027年分别实现归母净利润3.04/4.16/5.11亿元，对应PE分别为57/41/34倍，维持“推荐”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为29.65%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信建投的汤然。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000025132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","601881"],"gpt_icon":0},{"id":"2548846534","title":"中国银河：给予康泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2548846534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548846534?lang=zh_cn&edition=full","pubTime":"2025-07-03 07:30","pubTimestamp":1751499042,"startTime":"0","endTime":"0","summary":"中国银河证券股份有限公司程培,宋丽莹近期对康泰生物进行研究并发布了研究报告《PCV13获土耳其GMP认证，持续布局海外》，给予康泰生物买入评级。2024年土耳其全国人口总数约8566万，2023年新生儿数量约为95万。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为15.81。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300005071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601881","300601"],"gpt_icon":0},{"id":"2548502883","title":"康泰生物最新公告：股东袁莉萍拟减持不超过1.00%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2548502883","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548502883?lang=zh_cn&edition=full","pubTime":"2025-07-01 23:29","pubTimestamp":1751383777,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司持股5%以上股东袁莉萍计划自公告披露之日起十五个交易日后的三个月内，以集中竞价或大宗交易方式减持公司股份不超过11,160,000股，即不超过公司总股本的1.00%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100038325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0239","BK0046"],"gpt_icon":0},{"id":"2544927476","title":"康泰生物收盘下跌2.66%，滚动市盈率96.31倍，总市值163.74亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544927476","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544927476?lang=zh_cn&edition=full","pubTime":"2025-06-18 17:26","pubTimestamp":1750238795,"startTime":"0","endTime":"0","summary":"6月18日，康泰生物今日收盘14.66元，下跌2.66%，滚动市盈率PE达到96.31倍，总市值163.74亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均61.65倍，行业中值41.29倍，康泰生物排名第63位。股东方面，截至2025年3月31日，康泰生物股东户数62638户，较上次增加1383户，户均持股市值35.28万元，户均持股数量2.76万股。深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/18172651148701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0046","BK0239","300601","BK0201"],"gpt_icon":0},{"id":"2544938694","title":"【生物制品板块短线拉升 沃森生物涨超10%】生物制品板块短线拉升，沃森生物涨超10%，智飞生物、康泰生物、百克生物、康希诺、君实生物等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2544938694","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544938694?lang=zh_cn&edition=full","pubTime":"2025-06-17 09:55","pubTimestamp":1750125348,"startTime":"0","endTime":"0","summary":"生物制品板块短线拉升，沃森生物涨超10%，智飞生物、康泰生物、百克生物、康希诺、君实生物等跟涨。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/17095551106270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01877","300122","BK0070","BK0188","BK1515","LU1064131003.USD","BK1161","BK0201","LU1064130708.USD","LU2148510915.USD","LU2580892789.USD","BK0239","LU2580892862.HKD","BK0077","BK0046","300142","688276","BK1583","300601","688185","688180","LU1328615791.USD","BK0196"],"gpt_icon":0},{"id":"2544389879","title":"【疫苗股震荡拉升 沃森生物涨超10%】疫苗概念股盘中拉升，沃森生物、东富龙涨超10%，塞力医疗涨停，智飞生物、昭衍新药、康泰生物、华北制药涨超5%，冠昊生物、华兰疫苗等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2544389879","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544389879?lang=zh_cn&edition=full","pubTime":"2025-06-17 09:55","pubTimestamp":1750125343,"startTime":"0","endTime":"0","summary":"疫苗概念股盘中拉升，沃森生物、东富龙涨超10%，塞力医疗涨停，智飞生物、昭衍新药、康泰生物、华北制药涨超5%，冠昊生物、华兰疫苗等跟涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/17095551106267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2148510915.USD","301207","LU1064131003.USD","BK0077","LU1328615791.USD","BK0216","BK0028","LU2580892789.USD","BK0046","BK0250","BK0070","BK0201","BK1576","300601","BK0191","BK0251","LU2580892862.HKD","LU1064130708.USD","603127","BK0239","603716","BK0086","BK0042","300171","300142","06127","BK1141","600812","BK0188","300238","300122","BK0196","159646"],"gpt_icon":0},{"id":"2543655287","title":"每周股票复盘：康泰生物（300601）大宗交易机构净买入402.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543655287","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543655287?lang=zh_cn&edition=full","pubTime":"2025-06-14 07:28","pubTimestamp":1749857293,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘，康泰生物（300601）报收于14.53元，较上周的14.34元上涨1.32%。本周，康泰生物6月9日盘中最高价报15.56元。6月9日盘中最低价报14.36元。康泰生物当前最新总市值162.29亿元，在生物制品板块市值排名17/50，在两市A股市值排名954/5150。本周关注点交易信息汇总: 6月11日康泰生物现1笔大宗交易，机构净买入402.57万元交易信息汇总6月11日康泰生物现1笔大宗交易，机构净买入402.57万元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400009899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"gpt_icon":0},{"id":"2542330189","title":"6月11日康泰生物现1笔大宗交易 机构净买入402.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542330189","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542330189?lang=zh_cn&edition=full","pubTime":"2025-06-11 17:08","pubTimestamp":1749632899,"startTime":"0","endTime":"0","summary":"证券之星消息，6月11日康泰生物发生大宗交易，交易数据如下：大宗交易成交价格14.91元，成交27万股，成交金额402.57万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交2700.0手。截至2025年6月11日收盘，康泰生物报收于14.91元，下跌0.73%，换手率1.2%，成交量10.61万手，成交额1.59亿元。该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为15.81。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061100025869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","BK0046","300601"],"gpt_icon":0},{"id":"2542801855","title":"6月9日康泰生物涨5.79%，嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2542801855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542801855?lang=zh_cn&edition=full","pubTime":"2025-06-09 16:31","pubTimestamp":1749457884,"startTime":"0","endTime":"0","summary":"证券之星消息，6月9日康泰生物涨5.79%，收盘报15.17元，换手率3.24%，成交量28.69万手，成交额4.33亿元。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为2.75亿元，最新净值0.6515，较上一交易日下跌1.05%，近一年上涨5.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900020299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","300601","BK0046","BK0201"],"gpt_icon":0},{"id":"2539204652","title":"每周股票复盘：康泰生物（300601）实施权益分派并调整可转债转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2539204652","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539204652?lang=zh_cn&edition=full","pubTime":"2025-05-31 10:43","pubTimestamp":1748659386,"startTime":"0","endTime":"0","summary":"截至2025年5月30日收盘，康泰生物报收于14.29元，较上周的13.92元上涨2.66%。本周，康泰生物5月30日盘中最高价报14.45元。本周关注点公司公告汇总：康泰生物实施2024年年度权益分派，每10股派0.90元现金红利。公司公告汇总：“康泰转2”转股价格调整为15.73元/股，自2025年6月6日起生效。调整原因是公司实施2024年年度权益分派方案。该疫苗适用于2月龄及以上的婴幼儿，用于预防百日咳、白喉、破伤风。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053100008928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0239","BK0046"],"gpt_icon":0},{"id":"2538447150","title":"【康泰生物：三价流感病毒裂解疫苗临床试验申请获受理】康泰生物公告，公司和兰州百灵生物技术有限公司研发的三价流感病毒裂解疫苗（MDCK细胞）临床试验申请获得国家药品监督管理局受理。该疫苗适用于3周岁及以上人群，可预防疫苗相关型别的流感病毒引起的流行性感冒。国内尚无三价流感病毒裂解疫苗（MDCK细胞）获批上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2538447150","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538447150?lang=zh_cn&edition=full","pubTime":"2025-05-28 15:52","pubTimestamp":1748418779,"startTime":"0","endTime":"0","summary":"康泰生物公告，公司和兰州百灵生物技术有限公司研发的三价流感病毒裂解疫苗（MDCK细胞）临床试验申请获得国家药品监督管理局受理。该疫苗适用于3周岁及以上人群，可预防疫苗相关型别的流感病毒引起的流行性感冒。国内尚无三价流感病毒裂解疫苗（MDCK细胞）获批上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/28155250711324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","BK1141","03347","159646","300601","BK0201","BK0239","BK0046","BK1583"],"gpt_icon":0},{"id":"2529878929","title":"康泰生物：公司拥有国内先进的疫苗研发中心形成以自主研发为主的研发模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2529878929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529878929?lang=zh_cn&edition=full","pubTime":"2025-04-24 20:51","pubTimestamp":1745499090,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物04月23日在投资者关系平台上答复投资者关心的问题。感谢您对公司的关注！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400038165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300601","159646","BK0239","BK0201"],"gpt_icon":0},{"id":"2528854830","title":"图解康泰生物一季报：第一季度单季净利润同比减58.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528854830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528854830?lang=zh_cn&edition=full","pubTime":"2025-04-20 16:54","pubTimestamp":1745139251,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物2025年一季报显示，公司主营收入6.45亿元，同比上升42.85%；归母净利润2243.41万元，同比下降58.51%；扣非净利润1690.96万元，同比上升17.56%；负债率32.07%，财务费用703.35万元，毛利率73.46%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042000002584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0},{"id":"2528851998","title":"康泰生物(300601.SZ)发布一季度业绩，归母净利润2243.41万元，同比下降58.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528851998","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528851998?lang=zh_cn&edition=full","pubTime":"2025-04-20 16:45","pubTimestamp":1745138726,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)发布2025年第一季度报告，公司2025年第一季度营业收入6.45亿元，同比增长42.85%;归属于上市公司股东的净利润2243.41万元，同比下降58.51%;归属于上市公司股东的扣除非经常性损益的净利润1690.96万元，同比增长17.56%;基本每股收益0.02元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300601"],"gpt_icon":0},{"id":"2528851956","title":"康泰生物(300601.SZ)发布2024年度业绩，归母净利润2.02亿元，同比下降76.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528851956","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528851956?lang=zh_cn&edition=full","pubTime":"2025-04-20 16:42","pubTimestamp":1745138572,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)发布2024年年度报告，公司2024年度营业收入26.52亿元，同比下降23.75%;归属于上市公司股东的净利润2.02亿元，同比下降76.59%;归属于上市公司股东的扣除非经常性损益的净利润2.46亿元，同比下降65.93%;基本每股收益0.18元/股。拟每10股派发现金红利0.9元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300601"],"gpt_icon":0},{"id":"2516868943","title":"康泰生物最新公告：取得申报吸附破伤风疫苗生产的必备条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2516868943","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516868943?lang=zh_cn&edition=full","pubTime":"2025-03-03 18:29","pubTimestamp":1740997785,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，全资子公司民海生物近日收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告，研究结果显示该疫苗应用于成人免疫具有良好的安全性和免疫原性。该报告的取得表明吸附破伤风疫苗具备了申报生产的必备条件，若注册成功将丰富公司产品布局，增强核心竞争力。但该疫苗申报生产的进程和结果及产品上市进度具有不确定性，对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030300027092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239","159646"],"gpt_icon":0},{"id":"2516898026","title":"康泰生物(300601.SZ)子公司收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2516898026","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516898026?lang=zh_cn&edition=full","pubTime":"2025-03-03 18:28","pubTimestamp":1740997699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司全资子公司北京民海生物科技有限公司(“民海生物”)近日收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告，民海生物研发的吸附破伤风疫苗临床研究阶段工作顺利完成。研究结果显示，民海生物研制的吸附破伤风疫苗应用于成人免疫具有良好的安全性和免疫原性。本次吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告的取得表明吸附破伤风疫苗具备了申报生产的必备条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0201","BK1576","BK0239","BK1141","BK0046","03347","159646","300601"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753489427328,"stockEarnings":[{"period":"1week","weight":0.0741},{"period":"1month","weight":0.1463},{"period":"3month","weight":0.265},{"period":"6month","weight":0.2154},{"period":"1year","weight":0.1812},{"period":"ytd","weight":0.0297}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1048},{"period":"1year","weight":0.2449},{"period":"ytd","weight":0.0722}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"62638人(较上一季度增加2.26%)","perCapita":"14374股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111692万元","survey":"　　深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗。2024年公司荣获中国上市公司协会“2024年上市公司董事会典型实践案例”荣誉。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}